Pall Corp. To Open Latest Life Sciences Center of Excellence in New England

Updated

Pall Corp. To Open Latest Life Sciences Center of Excellence in New England

PORT WASHINGTON, N.Y.--(BUSINESS WIRE)-- Pall Corporation (NYSE:PLL), a global leader in filtration, separation and purification, today announced it will be opening a state-of-the-art Life Sciences Center of Excellence in Westborough, Massachusetts. Strategically located in the heart of Massachusetts' renowned life-science cluster, the new center will provide Pall life sciences customers in the northeast region of the United States a range of process solutions for drug development, validation support and training capabilities. The new Life Sciences center is scheduled to open in the spring of 2013.

"Our New England Life Sciences Center of Excellence is an important addition to our global network of customer support centers," said Ken Frank, President, Pall BioPharmaceuticals. "It will complement our new center in Menlo Park, Calif. and serve as a technical hub for our Life Sciences business and operations in the northeast region of the United States."


The 113,000 square-feet center will be equipped with new advanced life sciences equipment and will serve as a showcase for Pall technologies. These include: single-use systems (SUS), tangential flow filtration (TFF) systems, viral clearance and cell culture solutions, chromatography systems and others. The Westborough complex will serve as a proving ground for new technologies and applications development and will be designed to lead customers through the sequential stages of process flow. The center also will serve as a training facility for both Pall employees and customers.

Pall plans to transfer its existing operations and employees from its Northborough, Massachusetts location to the new center.

"The new Westborough facility provides an excellent opportunity for growth and will allow us to retain and attract talented scientists and engineers from the New England area," adds Frank.

Pall Life Sciences

Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. The company's membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce. Pall technologies are also used in clinical institutions and the food and beverage industries.

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Pall has been named a "top green company" by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.



Pall Corporation
Doug Novarro
Corporate Public Relations
5168019944
Follow us on Twitter @pallcorporation

KEYWORDS: United States North America Massachusetts New York

INDUSTRY KEYWORDS:

The article Pall Corp. To Open Latest Life Sciences Center of Excellence in New England originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement